# A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01495013` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01495013](<https://clinicaltrials.gov/study/NCT01495013>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01495013

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 427 participants.

## Technical summary

Registry record NCT01495013. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 427 participants (enrolled count; ClinicalTrials.gov record NCT01495013, source copy `cardio:ctgov-nct01495013-2016-11-21`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01495013, source copy `cardio:ctgov-nct01495013-2016-11-21`, retrieved 2026-10-26)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01495013, source copy `cardio:ctgov-nct01495013-2016-11-21`, retrieved 2026-10-26)
- Completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01495013, source copy `cardio:ctgov-nct01495013-2016-11-21`, retrieved 2026-10-26)
- Countries: Malaysia; Mexico; Philippines; Russia; South Korea; Thailand (ClinicalTrials.gov record NCT01495013, source copy `cardio:ctgov-nct01495013-2016-11-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01495013-2016-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): 1mg Glimepiride/10mg Atorvastatin FDC
- Intervention (Drug): 2mg Glimepiride/10mg Atorvastatin FDC
- Intervention (Drug): 3mg Glimepiride/10mg Atorvastatin FDC
- Intervention (Drug): 4mg Glimepiride/10mg Atorvastatin FDC
- Intervention (Drug): 1mg Glimepiride/20mg Atorvastatin FDC
- Intervention (Drug): 2mg Glimepiride/20mg Atorvastatin FDC
- Intervention (Drug): 3mg Glimepiride/20mg Atorvastatin FDC
- Intervention (Drug): 4mg Glimepiride/20mg Atorvastatin FDC
- Intervention (Drug): 1mg Glimepiride
- Intervention (Drug): 2mg Glimepiride
- Intervention (Drug): 3mg Glimepiride
- Intervention (Drug): 4mg Glimepiride
- Intervention (Drug): 10mg Atorvastatin
- Intervention (Drug): 20mg Atorvastatin
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: afed0d89ff0a155f89e23788fef6c5f13d19844a703c78462a48dfce1423bd47
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
